Abstract
The effect of varying plasma aluminum concentrations, ranging from 0 to 60 μg/ml aluminum, on the altered biodistribution of Tc-99m-Sn-diphosphonate was determined experimentally in rats. The results indicate that plasma aluminum levels of 20 μg/ml or greater result in increased soft tissue uptake of the radiopharmaceutical. This soft tissue uptake was predominantly liver and kidney. The higher plasma aluminum levels investigated (20 μg/ml or greater), which can cause an altered biodistribution of Tc-99m-Sn-diphosphonate in rats, can be found clinically in patients in a nuclear medicine department.